Mass General Brigham Ventures

Violet Therapeutics is a pre-clinical stage company leveraging first-in-class platforms to identify, map, and mine the cellular connectome. Violet’s drug discovery programs are focused on CNS diseases enabled by the novel targets elucidated by their platforms. Violet was co-founded by Mass General Brigham Ventures and scientists from Brigham & Women’s Hospital.

Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis. Its therapeutics target key fibrotic mediator proteins that aid in the development of fibrosis in chronically-damaged organs. The company was founded in 2019 and is headquartered in Cambridge, Massachusetts.

Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases. It seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Its platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies.

SwanBio Therapeutics is a developer of a therapeutic technology designed to deliver dramatic clinical efficacy for the treatment of neurological diseases. The company's technology focuses on the development and commercialisation of genetically defined therapies for the treatment of neurological disorders.

DexCare is a provider of platform-as-a-service offering to manage health system capacity and demand across all lines of care. The company enables health systems to evolve their traditional, one-to-one, patient-to-provider relationships and transform them into a highly scalable digital experience for their patients— increasing revenue from new, digital-first patients while minimizing new patient acquisition costs. DexCare was founded in 2021 and is headquartered in Seattle, WA.

Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases. It seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Its platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies.

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.

Lyndra Therapeutics is a company that develops medicines for long-term drug release in an oral dose form. The company is developing oral ultra-long-acting and sustained-release therapies for central nervous system (CNS) disorders for broad applicability across multiple therapeutic areas, including approved drugs, allowing the medical community to ensure improved medication adherence and health outcomes while also helping to lower healthcare costs.

Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties.

Carta Healthcare empowers hospitals to personalize the delivery of care to the individual needs of each patient. The approach Carta Healthcare is advocating and enabling to find past patients similar to the current one being treated, quantify what exactly happened to them during their journey through the hospital (this is where our model comes in), and use machine learning to project what the particular patient in question will need, and what the patient can expect their experience to be in the hospital.

SeQure Dx provides safety data for on and off-target CRISPR gene editing therapies

Abcuro’s mission is to develop immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by their founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system.

Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.

Scorpion Therapeutics is a clinical-stage oncology company specializing in precision medicine for cancer patients. It develops targeted small-molecule drugs to interact with validated cancer targets. It aims to leverage its platform to advance a broad pipeline of wholly-owned, optimized compounds across molecules targeting validated oncogene targets, molecules for previously undruggable targets, and molecules for novel cancer targets.

Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease. Founded by world-renowned experts in renal disease, Walden is applying its unique, systems-based approach to address the intersection between the pathology and biology of kidney disease.

ZielBio is an early-stage biotechnology company that identifies novel high-value disease targets and develops therapeutic interventions to improve patient outcomes. Its proprietary drug discovery platform Zielfind combines the power of functional, high throughput screening with large content data analytics to identify high-value targets. They have a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind. ZielBio was founded in 2011 and is based in Charlottesville, Virginia, United States.

Lyndra Therapeutics is a company that develops medicines for long-term drug release in an oral dose form. The company is developing oral ultra-long-acting and sustained-release therapies for central nervous system (CNS) disorders for broad applicability across multiple therapeutic areas, including approved drugs, allowing the medical community to ensure improved medication adherence and health outcomes while also helping to lower healthcare costs.

Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis. Its therapeutics target key fibrotic mediator proteins that aid in the development of fibrosis in chronically-damaged organs. The company was founded in 2019 and is headquartered in Cambridge, Massachusetts.

QurAlis is a clinical-stage biotechnology company that is developing precision medicines with genetically validated targets for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its proprietary platforms and biomarkers allow for the design and development of drugs that target disease-causing genetic alterations directly.

Pykus Therapeutics, Inc. was founded in 2016 to develop a dissolvable intraocular surgical device to make retinal surgery less painful and more successful. The co-founders were ophthalmology residents at the Massachusetts Eye and Ear Infirmary and Harvard Medical School when they developed a novel hydrogel to replace the use of intraocular gas during retinal surgery. This innovation will eliminate the extreme burden placed on patients including the requirement for face-down positioning, inability to see for weeks, and inability to fly for weeks.

Lyndra Therapeutics is a company that develops medicines for long-term drug release in an oral dose form. The company is developing oral ultra-long-acting and sustained-release therapies for central nervous system (CNS) disorders for broad applicability across multiple therapeutic areas, including approved drugs, allowing the medical community to ensure improved medication adherence and health outcomes while also helping to lower healthcare costs.

Massachusetts Eye and Ear Infirmly is the hospital specializing in research, education and treatment of eye and ear.

Health Catalyst is a tech platform that organizes and links health-related data from different systems. It helps organize, normalize, and link the data from all different systems and make it searchable by all users, even the non-technical.

T2 Biosystems is a private company developing a next-generation medical diagnostic platform that enables rapid and accurate diagnostic tests of all types on a single, easy-to-use instrument. The company's proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time-consuming sample preparation.

T2 Biosystems is a private company developing a next-generation medical diagnostic platform that enables rapid and accurate diagnostic tests of all types on a single, easy-to-use instrument. The company's proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time-consuming sample preparation.

T2 Biosystems is a private company developing a next-generation medical diagnostic platform that enables rapid and accurate diagnostic tests of all types on a single, easy-to-use instrument. The company's proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time-consuming sample preparation.

Provasculon was founded to exploit the discovery by Richard Lee, MD, a cardiologist at Brigham and Women's Hospital and Associate Professor at Harvard Medical School, and Vincent Segers, MD, a researcher at Brigham and Women's Hospital, of novel forms of the growth factor Stromal Cell-Derived Factor-1 (SDF-1).

Tattoos are all about self-expression and personal style; they're a way to showcase your unique point of view. And how many times have you changed your mind? Remember Angelina's ode to Billy Bob? We all know their love didn't last as long as the art commemorating it. Freedom2 was founded nearly ten years ago with the crazy idea that a permanent tattoo might be removable. Typical tattoo ink is made from insoluble pigments and remains in the skin forever. Laser treatments can be costly and painful, and ultimately might not even remove the tattoo completely. Thinking that there's got to be a better alternative, our founders began pursuing the idea that there could be a way to make tattoos that were permanent, and less expensive to remove. And thus the idea of the Particle Encapsulation and Enhancement (P2E) Platform was born.

GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.

Radianse provides intelligent solutions for businesses with their real-time tracking services. Their advanced software automatically collects and processes a variety of live data on any asset. The situation history is recorded and easily accessible through their Radianse Awareness Suite from any web-enabled device. Their mission is to improve the way businesses operate by providing accessible, affordable, andcustomized solutions that automatically integrate data sources into real-time actionable intelligence. They aim to be the market leader in the providing of situation awareness coupled with actionable intelligence. Their goal is to deliver innovative, technology-based applications that allow their customers to manage their resources, control costs, increase revenue opportunities, and improve overall operational efficiency. Radianse has achieved significant milestones in developing cutting-edge algorithms and methodologies to deliver reliable products with superior accuracy and performance. All of their products are covered by one or more patents with additional U.S. and international patents pending. Radianse is committed to constantly innovating and evolving. They began as an engineering organization focused on Radio Frequency Identification (RFID) technology-based solutions. Their aim was to automatically and continuously monitor high-value hospital assets. Radianse now works with many clients from various industries. Radianse remains focused on being committed to innovative research and development. Radianse is applying its leadership and extensive networking knowledge along with inventive technology designs to launch new and advanced applications. They are committed to innovation and delivering intelligent solutions for any industry.